BPUR - Biopure Corporation Class A

Your Recent Quotes: 0 | 0

Biopure Corporation Class A

TRADE NOW Related Information and Financials
Price Glossary Definition
0.13 0.05
62.30%
11/21/08 3:59
Open
0.10
Prev Close
0.08
Volume
575,130
52 Wk. Range
0.07- 0.74
Year-to-Date Performance Glossary Definition
DOWN -79.69%
Latest Dividend
Dividend
N/A
Yield
0.00
Ex-Date
N/A
Price/Earnings Comparisons Glossary Definition
 
-0.05
 
0.00
 
12.60
BPUR
Sect. Av.
S&P 500
Market Cap
2,987,200
Outstanding Shares
34,971,000
TheStreet Rating Glossary Definition
  • A
  • B
  • C
  • D
  • E
Buy BPUR Rating Report
Target Price (1Yr)
High
0.00
Revenue
0

Annual Dividend
Rate
0.00
Yield
0.00
Growth
12 Month
3 Year
CAGR
Revenue
49.00
-0.32
-0.12
Net Income
N/A
-0.13
0.00
EPS
N/A
-0.90
0.00

Stock Performance History
 
3 Month
1 Year
3 Year
Price Change
-60.61
-80.60
-85.56
Earnings Per Share($)

10/2005
 
 
 
-6.40
10/2006
 
 
 
-3.35
10/2007
 
 
 
-2.43

Earnings
EBITDA
-22,711,000
Revenue
2,556,000
Outside Analyst Rating History

11/22/08
0
Buy
11/22/08
Hold
11/22/08
0
Sell

Jim Cramer Portfolio
Find out now if BPUR is in Jim's personal portfolio at Action Alerts PLUS.

Price & Volume

Compare This Stock
Latest Headlines
Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.

9:26AM 04/30/08

Vertex's cystic fibrosis compound shows promise, but be cautious in your enthusiasm. Also, an update on the quest for blood substitutes.

12:01PM 03/29/08

Flotek sinks.

4:01PM 11/01/07

It's hard to believe the blood-substitute maker didn't know of the heart attack risks earlier.

12:04AM 08/07/07

The company's confidence in approval for its blood substitute disregards its own data.

12:10AM 06/20/07

Data discrepancies will mean a reanalysis of a clinical trial. The stock sinks 55%.

5:59PM 12/19/06

As the Dow hits a new high, money manager Ken Fisher explains why stocks will keep rallying in '07.

5:42PM 12/15/06

Genta plunges as regulators say its cancer treatment is not approvable.

1:55PM 12/15/06

Shares fall 29%.

12:55PM 12/15/06

Inspire Pharmaceuticals' dry-eye treatment fails to inspire FDA approval.

3:04PM 12/02/05

Understanding the Market

Our Experts' Take at RealMoney
However, option traders boost January calls.

4:37PM 11/21/08

This market is producing a few stocks that could represent exceptional opportunities.

3:03PM 11/21/08

More Experts' Takes


Premium Stock Ideas
Is Cramer trading BPUR in his Action Alerts Plus Portfolio?

Premium Services